PsychedelicNewsBreaks

MondayAug 23, 2021 12:53 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp delves into the evolution of psychedelics from an ancient antidote “to breakthrough medicine with massive therapeutic potential for a wide range of notoriously hard-to-treat diseases.” “With these strict legal changes around the world, the psychedelics industry became largely inactive. But today, an explosion of unprecedented…

Continue Reading

ThursdayAug 19, 2021 9:31 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under the Patent Cooperation Treaty (“PCT”). One of the patent applications concerns a group of proprietary compounds that the company has identified as important for further evaluation toward selection as potential therapeutics. The other application regards claims and disclosures toward other proprietary novel psychedelic compounds, including…

Continue Reading

TuesdayAug 17, 2021 2:50 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a clinical trial for eating disorders including binge eating and hypothalamic obesity. “With the growing popularity and proliferation of psychedelics, many companies are pursuing therapeutic indications with the compounds,” reads a recent article discussing Tryp’s positioning. “However, very few have initiated phase 2a studies. Tryp Therapeutics…

Continue Reading

TuesdayAug 17, 2021 10:40 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. nonprovisional application claiming priority to the May 2021 PCT application. The company noted that the International Patent Searching authority had written an opinion supporting novelty, inventive steps and industrial applicability to multiple claims within Cybin’s patent filing, including claims to compositions and methods that support…

Continue Reading

MondayAug 16, 2021 10:04 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Financial, Business Results

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced its unaudited business highlights and financial results for the three-month period ended June 30, 2021. In the report, the company noted it had become the first psychedelic company to list on the NYSE American LLC stock exchange, a milestone reached on Aug. 5, 2021; raised more than C$120 million with the inclusion of its latest equity financing round; achieved certain milestones by wholly owned subsidiary Adelia Therapeutics Inc.; initiated the next phase of its digital therapeutics platform designed to evaluate patient outcomes through a highly secure, patient-centered data…

Continue Reading

FridayAug 13, 2021 11:55 am

PsychedelicNewsBreaks – Microdose Psychedelic Insights to Deep Dive into World of Psychedelic Medicine Investment at Upcoming Conference

Microdose Psychedelic Insights, a cutting-edge media company aiming to move the psychedelics industry to the forefront of modern medicine, today announced that it will host the upcoming Psychedelic Capital conference. The virtual event is slated to take place on August 31, 2021, and provide attendees with access to the top companies, latest IPOs, newest opportunities, and deepest industry insights in the growing psychedelic medicine sector. As part of a series of conferences diving deep into the world of psychedelic medicine investment, the event seeks to introduce investors and attendees to a curated group of CEOs, capital advisors and investment luminaries…

Continue Reading

FridayAug 13, 2021 9:37 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Reports Q1 Milestones for Subsidiary¬ — Notes Corrected Information

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Those milestones are for Year 1 Q3 (i)-(iii) and Year 1 Q4 (i) and (iii), as contemplated by the terms of the Dec. 7, 2020, agreement. Consequently, the company announced that, in accordance with the agreement, Class B common shares will be issued to Adelia shareholders to…

Continue Reading

ThursdayAug 12, 2021 11:21 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Q1 Milestones for Subsidiary

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Consequently, the company announced that, in accordance with the agreement, Class B common shares will be issued to Adelia shareholders to satisfy the  $379,021.24 due to them on meeting of the relevant milestones. Those shares are exchangeable for common shares in the capital of Cybin, the…

Continue Reading

WednesdayAug 11, 2021 2:15 pm

PsychedelicNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance,” reads a recent article discussing the company. “Cancer Differentiation Analysis (‘CDA’) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins…

Continue Reading

TuesdayAug 10, 2021 10:15 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnerships to Explore, Develop Proprietary Psilocybin Formulations

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has signed agreements with both Calvert Labs and Gad Consulting Services to design, execute and collaborate on exploratory studies related to Tryp's Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM) (“PFN”), program. An Altasciences company, Calvert Labs has established an impressive track record of executing FDA-approved studies across a broad range of therapeutic indications. The two companies will work together to generate toxicology and blood exposure level data related to Tryp's proprietary, psilocybin-based formulation, TRP-8803; the agreement also outlines collaboration to strengthen…

Continue Reading